Gemcitabine plus irinotecan as first-line weekly therapy in locally advanced and/or metastatic pancreatic cancer - PubMed

Affiliations

• PMID: 19806786
• DOI: 10.3727/096504009789745610

Clinical Trial

Gemcitabine plus irinotecan as first-line weekly therapy in locally advanced and/or metastatic pancreatic cancer

B Neri et al. Oncol Res. 2009.

Abstract

Single-agent gemcitabine has been established as standard treatment for advanced pancreatic cancer since clinical studies have shown an improvement in overall survival and significant clinical benefit when compared to the best supportive care despite low overall objective response. Several phase II studies have tested other single agents and different gemcitabine-based regimens in pancreatic cancer, but both response and survival rates have remained low. Irinotecan, a topoisomerase I inhibitor currently approved for the treatment of metastatic colon cancer, has also demonstrated improved response rate in patients with pancreatic cancer. Our purpose was to determine the activity and toxicity of this regimen in patients with unresectable or metastatic pancreatic cancer. Patients with histologically confirmed pancreatic adenocarcinoma received gemcitabine 1000 mg/m2 plus irinotecan 100 mg/m2 IV on days 1, 8, and 15 of a 28-day cycle for 6-8 months. From February 2004 to April 2006, 33 patients were entered into this study, 32 of whom were evaluable for treatment response, toxicity, median time to progression, and median survival. Characteristics included a median age of 63 years (range 41-79), 21 males (64%), and 12 females (36%). One patient discontinued treatment due to adverse effects. The total number of cycles administered was 188 and the median number of cycles for patients was 5.6 (range 2-7). Thirty-two patients were assessable for toxicity and response. Grade 3 hematological toxicity occurred in 9% of patients and was primarily neutropenia. No grade >2 gastrointestinal toxicities or death due to treatment were observed. The most frequent nonhematological adverse event was fatigue. Ten patients responded to treatment with two complete responses (6.3%) and eight partial responses (25.0%), for an overall response rate of 31.3%; 11 patients achieved stable disease (34.3%). The median time to tumor progression and the median survival were 9.2 (95% CI: 6.0-12.4) and 11.8 (95% CI: 7.7-15.9) months, respectively, with a 2-year survival of 22%. On the basis of this trial, the combination of gemcitabine plus irinotecan, administered in a weekly schedule and at this dose, is well tolerated and offers encouraging activity in the treatment of advanced and/or metastatic pancreatic cancer.

Similar articles

• Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer.

  Mishra G, Butler J, Ho C, Melin S, Case LD, Ennever PR, Magrinat GC, Bearden JD, Minotto DC, Howerton R, Levine E, Blackstock AW. Mishra G, et al. Am J Clin Oncol. 2005 Aug;28(4):345-50. doi: 10.1097/01.coc.0000159559.42311.c5. Am J Clin Oncol. 2005. PMID: 16062075 Clinical Trial.

• Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.

  Kozuch P, Grossbard ML, Barzdins A, Araneo M, Robin A, Frager D, Homel P, Marino J, DeGregorio P, Bruckner HW. Kozuch P, et al. Oncologist. 2001;6(6):488-95. doi: 10.1634/theoncologist.6-6-488. Oncologist. 2001. PMID: 11743211

• A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer.

  Sun W, Hewitt MR, Theobald MR, Hershock D, Haller DG. Sun W, et al. Cancer. 2007 Dec 15;110(12):2768-74. doi: 10.1002/cncr.23098. Cancer. 2007. PMID: 17932893 Clinical Trial.

• Irinotecan/gemcitabine combination chemotherapy in pancreatic cancer.

  Rocha Lima CM, Sherman CA, Brescia FJ, Brunson CY, Green MR. Rocha Lima CM, et al. Oncology (Williston Park). 2001 Mar;15(3 Suppl 5):46-51. Oncology (Williston Park). 2001. PMID: 11301841 Review.

• Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.

  Rocha Lima CM, Rizvi NA, Zhang C, Herndon JE 2nd, Crawford J, Govindan R, King GW, Green MR; Cancer Leukemia Group B. Rocha Lima CM, et al. Ann Oncol. 2004 Mar;15(3):410-8. doi: 10.1093/annonc/mdh104. Ann Oncol. 2004. PMID: 14998842 Review.

Cited by

• Intervention of mirtazapine on gemcitabine-induced mild cachexia in nude mice with pancreatic carcinoma xenografts.

  Jiang SM, Wu JH, Jia L. Jiang SM, et al. World J Gastroenterol. 2012 Jun 14;18(22):2867-71. doi: 10.3748/wjg.v18.i22.2867. World J Gastroenterol. 2012. PMID: 22719198 Free PMC article.

• Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress.

  Gilliam LA, St Clair DK. Gilliam LA, et al. Antioxid Redox Signal. 2011 Nov 1;15(9):2543-63. doi: 10.1089/ars.2011.3965. Epub 2011 Jun 15. Antioxid Redox Signal. 2011. PMID: 21457105 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal